TY - JOUR
T1 - Acyclovir and other chemotherapy for herpes group viral infections.
AU - Balfour, H. H.
PY - 1984
Y1 - 1984
N2 - The recent profusion of antiviral research has resulted in significant advances toward prevention and treatment of herpes group virus infections. The most promising new agent is acyclovir, which is available in topical, intravenous, and oral formulations. Results of clinical trials of acyclovir for prevention and treatment of herpes simplex, varicella-zoster virus, cytomegalovirus, and Epstein-Barr virus infections are discussed, and the potential problem of antiviral resistance considered. Vidarabine therapy is reviewed briefly, and future new drugs with activity against herpesviruses are mentioned.
AB - The recent profusion of antiviral research has resulted in significant advances toward prevention and treatment of herpes group virus infections. The most promising new agent is acyclovir, which is available in topical, intravenous, and oral formulations. Results of clinical trials of acyclovir for prevention and treatment of herpes simplex, varicella-zoster virus, cytomegalovirus, and Epstein-Barr virus infections are discussed, and the potential problem of antiviral resistance considered. Vidarabine therapy is reviewed briefly, and future new drugs with activity against herpesviruses are mentioned.
UR - http://www.scopus.com/inward/record.url?scp=0021307961&partnerID=8YFLogxK
UR - http://www.scopus.com/inward/citedby.url?scp=0021307961&partnerID=8YFLogxK
U2 - 10.1146/annurev.me.35.020184.001431
DO - 10.1146/annurev.me.35.020184.001431
M3 - Review article
C2 - 6326661
AN - SCOPUS:0021307961
SN - 0066-4219
VL - 35
SP - 279
EP - 291
JO - Annual review of medicine
JF - Annual review of medicine
ER -